Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.002 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0137 | 1 | 1 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.002 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0137 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0137 | 1 | 1 |
Mycobacterium ulcerans | DNA polymerase IV | 0.002 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0137 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0137 | 1 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0137 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.002 | 0 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0137 | 1 | 1 |
Mycobacterium ulcerans | DNA polymerase IV | 0.002 | 0 | 0.5 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.002 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0 | 0.5 |
Leishmania major | DNA polymerase kappa, putative | 0.002 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.002 | 0 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0137 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0 | 0.5 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.002 | 0 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.002 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0137 | 1 | 1 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.002 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.002 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 0 | 0.5 |
Leishmania major | DNA polymerase kappa, putative,DNA polymerase IV, putative | 0.002 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.002 | 0 | 0.5 |
Leishmania major | DNA polymerase eta, putative | 0.002 | 0 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.002 | 0 | 0.5 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.002 | 0 | 0.5 |
Trypanosoma brucei | unspecified product | 0.002 | 0 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0137 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.002 | 0 | 0.5 |
Echinococcus multilocularis | tar DNA binding protein | 0.0137 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0137 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.002 | 0 | 0.5 |
Giardia lamblia | DINP protein human, muc B family | 0.002 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = -1.45 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = -1.08 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = -1.01 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 3 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 8 % | GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM. | ChEMBL. | 20485427 |
Inhibition (functional) | = 36 % | GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 89 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition frequency index (IFI) (functional) | = 2.14 | Inhibition Frequency Index (IFI) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 3 % | Percent inhibition of P. falciparum lactate dehydrogenase activity (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 8 % | Percent inhibition of HepG2 growth (at 10 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 36 % | Percent inhibition of P. falciparum Dd2 growth (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 89 % | Percent inhibition of P. falciparum 3D7 growth (at 2 uM) | GSK. | 20485427 |
XC50 (functional) | = 5.95 | XC50 determination of P. falciparum 3D7 growth | GSK. | 20485427 |
XC50 (functional) | = 1.11524 uM | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth. | ChEMBL. | 20485427 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.